WHITEPAPER | WHAT'S HOT & WHAT'S NOT IN IMMUNO-ONCOLOGY LICENSING

What's Hot & What's Not in Immuno-Oncology Licensing

This whitepaper is based on two live web panels and discusses what’s exciting in immuno-oncology drug development versus what is not popular in licensing, and why. 

For the live events, biotech licensing and pharmaceutical business development consultant Linda Pullan was joined by four panelists who are business development experts from global pharmaceutical companies, a leading academic cancer center, and a top business development consulting firm.

If you are developing a cancer drug or working toward in- or out-licensing of a cancer drug, you will want to read these perspectives.



VIEW THE
WHITEPAPER

WHITEPAPER AUTHOR:

Company team

Linda Pullan, PhD

Pullan Consulting

Linda offers biotech and pharmaceutical companies consulting in all aspects of partnering. Linda has a Ph.D. in Biochemistry, a B.S. in Chemistry, and more than twenty years of drug industry experience. Learn More

Company team

Jeff Bockman, PhD

Vice President, Defined Health

Jeff leads the Oncology and Virology Practices at Defined Health. He received a BA from University of California at San Diego, a PhD in Medical Microbiology from the University of California at Berkeley, and an MA in English/Creative Writing from New York University. Learn More

Company team

Axel Hoos, MD, PhD

Vice President, Oncology R&D and Head of Immuno-Oncology at GlaxoSmithKline Pharmaceuticals (GSK)

Axel builds the immuno-oncology portfolio of GSK across the modalities of antibodies, small molecules, bispecific molecules and cell & gene therapies, for which he directs clinical and discovery research. Learn More

Company team

Ferran Prat, PhD

VP of Strategic Industry Ventures, MD Anderson

Ferran helps the faculty and researchers at MD Anderson develop collaborative opportunities with pharmaceutical, biotech, diagnostics, imaging, laboratory medicine and other industry partners. Learn More

Company team

Nathan Sanburn, MS

East Region Director, Medical Oncology, Eli Lilly & Company

Nathan Sanburn currently serves as the Strategy and Business Development Director for the Oncology Business Unit at Lilly. He is a molecular biologist by training, with over 19 years of experience across R&D, clinical trials, and business transactions.

SPONSORED BY